merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
Company profile
Ticker
MACK
Exchange
Website
CEO
Gary L. Crocker
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Merrimack Pharmaceuticals UK Limited • Merrimack Securities Corporation ...
MACK stock data
Latest filings (excl ownership)
DEFR14A
Revised proxy
1 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
8-K
Merrimack Receives $225 Million Milestone Payment from Ipsen
27 Mar 24
DEFA14A
Additional proxy soliciting materials
22 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
10-K/A
2023 FY
Annual report (amended)
21 Mar 24
425
Business combination disclosure
7 Mar 24
8-K
Merrimack Reports Full Year 2023 Financial Results
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
PRE 14A
Preliminary proxy
5 Mar 24
Latest ownership filings
SC 13G/A
BlackRock Inc.
7 Mar 24
SC 13G/A
22NW Fund, LP
14 Feb 24
SC 13G
BlackRock Inc.
31 Jan 24
SC 13D/A
Newtyn Management, LLC
25 Jan 24
4
Eric Andersen
28 Dec 23
SC 13D/A
Western Standard LLC
13 Dec 23
4
Eric Andersen
11 Dec 23
4
Eric Andersen
20 Nov 23
4
Eric Andersen
16 Nov 23
4
Eric Andersen
14 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.08 mm | 6.08 mm | 6.08 mm | 6.08 mm | 6.08 mm | 6.08 mm |
Cash burn (monthly) | 1.35 mm | 584.00 k | 177.00 k | 179.50 k | 67.67 k | 117.67 k |
Cash used (since last report) | 9.32 mm | 4.03 mm | 1.22 mm | 1.24 mm | 467.48 k | 812.91 k |
Cash remaining | -3.24 mm | 2.05 mm | 4.86 mm | 4.84 mm | 5.62 mm | 5.27 mm |
Runway (months of cash) | -2.4 | 3.5 | 27.5 | 27.0 | 83.0 | 44.8 |
Institutional ownership, Q2 2023
78.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 64 |
Opened positions | 19 |
Closed positions | 8 |
Increased positions | 18 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 95.73 bn |
Total shares | 11.38 mm |
Total puts | 32.00 k |
Total calls | 151.70 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Newtyn Management | 1.87 mm | $23.05 bn |
Western Standard | 1.67 mm | $20.57 bn |
JFL Capital Management | 1.25 mm | $6.00 mm |
Biotechnology Value Fund L P | 1.11 mm | $8.20 mm |
22NW Fund | 1.02 mm | $0.00 |
BLK Blackrock | 676.29 k | $8.32 bn |
Vanguard | 556.80 k | $6.85 bn |
Madison Avenue Partners | 553.09 k | $6.80 bn |
Dimensional Fund Advisors | 459.96 k | $5.66 bn |
Sepio Capital | 294.55 k | $3.62 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Dec 23 | Andersen Eric | Common Stock | Buy | Acquire P | Yes | No | 13.3503 | 857 | 11.44 k | 534,008 |
26 Dec 23 | Andersen Eric | Common Stock | Buy | Acquire P | Yes | No | 13.15 | 48,693 | 640.31 k | 533,151 |
7 Dec 23 | Andersen Eric | Common Stock | Buy | Acquire P | Yes | No | 12.8498 | 24,666 | 316.95 k | 484,458 |
7 Dec 23 | Andersen Eric | Common Stock | Buy | Acquire P | Yes | No | 12.8498 | 76,384 | 981.52 k | 1,735,600 |
17 Nov 23 | Andersen Eric | Common Stock | Buy | Acquire P | Yes | No | 12.5 | 65 | 812.50 | 459,792 |
17 Nov 23 | Andersen Eric | Common Stock | Buy | Acquire P | Yes | No | 12.5 | 235 | 2.94 k | 1,659,216 |
14 Nov 23 | Andersen Eric | Common Stock | Buy | Acquire P | Yes | No | 12.5 | 10,887 | 136.09 k | 459,727 |
14 Nov 23 | Andersen Eric | Common Stock | Buy | Acquire P | Yes | No | 12.5 | 39,283 | 491.04 k | 1,658,981 |
13 Nov 23 | Andersen Eric | Common Stock | Buy | Acquire P | Yes | No | 12.3876 | 3,379 | 41.86 k | 448,840 |
13 Nov 23 | Andersen Eric | Common Stock | Buy | Acquire P | Yes | No | 12.3876 | 12,191 | 151.02 k | 1,619,698 |
News
Merrimack Secures $225M Milestone Payment From Ipsen; Says It Is Unlikely That Any Additional Milestone Payments Will Become Payable
27 Mar 24
Ipsen's Onivyde Regimen, A Potential New Standard-Of-Care First-Line Therapy In Metastatic Pancreatic Adenocarcinoma, Approved By FDA
13 Feb 24
FDA Approves Irinotecan Liposome For First-line Treatment Of Metastatic Pancreatic Adenocarcinoma
13 Feb 24
Press releases
Merrimack Receives $225 Million Milestone Payment from Ipsen
27 Mar 24
Merrimack Reports Full Year 2023 Financial Results
7 Mar 24
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
13 Feb 24